Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sara Stumpo
Observed name:
S. Stumpo
Institutions:
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
University of Bologna
Observed institutions:
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
University of Bologna
ORCID:
0009-0006-7433-4347
Observed ORCID:
0009-0006-7433-4347
OpenAlex ID:
A5093504668
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
2025
·
Alessandro Di Federico
, Sara Stumpo
, et al.
·
The Lancet Oncology
·
67
Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives
2023
·
Sara Stumpo
, Maria Giovanna Formelli
, et al.
·
Journal of Clinical Medicine
·
26
PDF
Efficacy and Safety of TROP-2-Targeting Antibody–Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data
2025
·
Sara Stumpo
, Andrea Carlini
, et al.
·
Cancers
·
9
PDF
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis
2026
·
Alessandro Di Federico
, Samuele Compagno
, et al.
·
JAMA Oncology
·
6
Efficacy of Adding Immune Checkpoint Inhibition to Chemotherapy, With or Without VEGF Inhibition, in Patients With Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis With Reconstructed Individual Patient Data
2026
·
Alessandro Di Federico
, Sara Stumpo
, et al.
·
JTO Clinical and Research Reports
·
1
Clinicogenomic determinants of early progression on first-line osimertinib in EGFR-mutant NSCLC
2026
·
Federica Pecci
, Mark Y. Jeng
, et al.
·
Journal of Thoracic Oncology
Data from Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non–Small Cell Lung Cancer Receiving First-line Osimertinib
2026
·
Alessandro Di Federico
, Federica Pecci
, et al.
Supplementary Tables1 from Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non–Small Cell Lung Cancer Receiving First-line Osimertinib
2026
·
Alessandro Di Federico
, Federica Pecci
, et al.
Supplementary Figures1 from Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non–Small Cell Lung Cancer Receiving First-line Osimertinib
2026
·
Alessandro Di Federico
, Federica Pecci
, et al.
Lurbinectedin in the therapeutic landscape of SCLC: Key clinical evidence and evolving role in the era of emerging therapies
2026
·
Andrea Monte
, Elisa Andrini
, et al.
·
Critical Reviews in Oncology/Hematology
Clinical Significance of EGFR Amplification in Patients with EGFR -Mutated Metastatic Non–Small Cell Lung Cancer Receiving First-line Osimertinib
2026
·
Alessandro Di Federico
, Federica Pecci
, et al.
·
Clinical Cancer Research
PP01.47: PD-(L)1 Inhibitor Monotherapy Versus Chemo-Immunotherapy for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and PD-L1 Expression ≥50%: A Systematic Review and Meta-Analysis with Individual Patient Data
2026
·
Alessandro Di Federico
, Samuele Compagno
, et al.
·
Journal of Thoracic Oncology
PP01.20: Integrating Clinicopathologic and Genomic Features to Identify Patients at Risk of Earlier Progression to First-Line Osimertinib in EGFR-Mutant NSCLC
2026
·
Federica Pecci
, Mark Jeng
, et al.
·
Journal of Thoracic Oncology
P1.11.42 Dual Immune Checkpoint Blockade With CTLA-4 and PD-(L)1 Inhibitors in NSCLC: A Reconstructed Patient Data Meta-Analysis
2025
·
A. Di Federico
, S. Stumpo
, et al.
·
Journal of Thoracic Oncology
Show more works
View as search
Works count:
14
Citation count:
109
H-index:
4
I10-index:
2
Year
Topic
Type